Genelux Corporation
Support and Resistance Levels
Past performance
News About GNLX
All events for GNLX
All deals for GNLX
Financial Ratios
Financial Statements
GNLX vs Sector & Peers
About Genelux Corporation
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California. Website genelux.com
Headquarters Westlake Village, CA, US